Ignite Creation Date:
2025-12-24 @ 6:49 PM
Ignite Modification Date:
2026-02-28 @ 11:18 AM
Study NCT ID:
NCT05088057
Status:
UNKNOWN
Last Update Posted:
2021-10-21
First Post:
2021-10-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer
Sponsor:
Aiping Shi
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
2021-TNBC-01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None